DOCSLIB.ORG

Appendix F9. University of Maryland Health Partners (UMHP) Prescription Drugs Subject to Nqtls, by Delivery System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Appendix F9. University of Maryland Health Partners (UMHP) Prescription Drugs Subject to Nqtls, by Delivery System Appendix F9. University of Maryland Health Partners (UMHP) Prescription Drugs Subject to NQTLs, by Delivery System Prior Authorization (PA) NQTL Fail First/Step Therapy (FF/ST) NQTL Prescription Drug Formulary Med/Surg Drugs Med/Surg Drugs CETIRIZINE-PSEUDOEPHEDRINE TAB ER 12HR 5-120 MG TAMOXIFEN CITRATE TAB 20 MG (BASE EQUIVALENT) PROGESTERONE MICRONIZED CAP 100 MG *PEDIATRIC MULTIPLE VITAMIN W/ C & FA CHEW TAB** *RESPIRATORY THERAPY SUPPLIES - MISC** SARILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML Y CALCIUM CITRATE-VITAMIN D TAB 250 MG-200 UNIT (ELEMENTAL CA) PANCRELIPASE (LIP-PROT-AMYL) DR CAP 12000-38000-60000 UNIT *NEOMYCIN-BACITRACIN-POLYMYXIN OINT*** SENNOSIDES-DOCUSATE SODIUM TAB 8.6-50 MG DIPHENHYDRAMINE HCL (SLEEP) TAB 25 MG *MULTIPLE VITAMINS W/ MINERALS TAB** LEUCOVORIN CALCIUM TAB 10 MG *ADHESIVE BANDAGES*** *WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT*** *MULTIPLE VITAMINS W/ MINERALS TAB** BISACODYL SUPPOS 10 MG CHOLECALCIFEROL CHEW TAB 10 MCG (400 UNIT) LAMIVUDINE TAB 150 MG NORETHINDRONE ACETATE-ETHINYL ESTRADIOL TAB 1 MG-5 MCG NADOLOL TAB 80 MG NITROGLYCERIN TD PATCH 24HR 0.6 MG/HR *LACTOBACILLUS CAP** *ADHESIVE BANDAGES*** *MULTIPLE VITAMIN TAB** *SPECIALITY VITAMIN PRODUCT TAB** NYSTATIN TOPICAL POWDER 100000 UNIT/GM PIOGLITAZONE HCL-METFORMIN HCL TAB 15-500 MG *ADHESIVE BANDAGES*** DEXTROMETHORPHAN-GUAIFENESIN LIQUID 10-100 MG/5ML *BLOOD GLUCOSE MONITORING KIT W/ DEVICE*** *ADHESIVE BANDAGES*** LIDOCAINE PATCH 4% Appendix F9 1 Appendix F9. University of Maryland Health Partners (UMHP) Prescription Drugs Subject to NQTLs, by Delivery System Prior Authorization (PA) NQTL Fail First/Step Therapy (FF/ST) NQTL Prescription Drug Formulary Med/Surg Drugs Med/Surg Drugs DOCUSATE SODIUM CAP 50 MG *MULTIPLE VITAMIN TAB** FREMANEZUMAB-VFRM SUBCUTANEOUS SOLN PREF SYR 225 MG/1.5ML Y *PEDIATRIC MULTIPLE VITAMINS W/ FLUORIDE CHEW TAB 0.25 MG*** *MULTIPLE VITAMINS W/ MINERALS TAB** DESOGESTREL & ETHINYL ESTRADIOL TAB 0.15 MG-30 MCG *MULTIPLE VITAMINS W/ MINERALS CAP** *MULTIPLE VITAMIN TAB** UREA CREAM 40% *PEDIATRIC MULTIPLE VITAMINS W/ FLUORIDE SOLN 0.5 MG/ML*** SIMETHICONE CHEW TAB 125 MG ASPIRIN TAB 325 MG *ADHESIVE BANDAGES*** *ADHESIVE BANDAGES*** BISACODYL TAB DELAYED RELEASE 5 MG TENOFOVIR DISOPROXIL FUMARATE TAB 200 MG *ADHESIVE BANDAGES*** *LANCETS*** LEFLUNOMIDE TAB 10 MG *SPACER/AEROSOL-HOLDING CHAMBERS - DEVICE*** LORATADINE TAB 10 MG FUROSEMIDE TAB 80 MG IBUPROFEN CHEW TAB 100 MG GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML *ADHESIVE BANDAGES*** *ADHESIVE BANDAGES*** *VITAMINS W/ LIPOTROPICS TAB** POTASSIUM CHLORIDE CAP ER 8 MEQ ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML Y ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML Y INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16") ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML Y OCTREOTIDE ACETATE INJ 100 MCG/ML (0.1 MG/ML) Y Appendix F9 2 Appendix F9. University of Maryland Health Partners (UMHP) Prescription Drugs Subject to NQTLs, by Delivery System Prior Authorization (PA) NQTL Fail First/Step Therapy (FF/ST) NQTL Prescription Drug Formulary Med/Surg Drugs Med/Surg Drugs *MULTIPLE VITAMINS W/ MINERALS TAB** LOSARTAN POTASSIUM TAB 50 MG LAMIVUDINE ORAL SOLN 10 MG/ML CHOLESTYRAMINE LIGHT POWDER PACKETS 4 GM POVIDONE-IODINE OINT 10% *PEDIATRIC VITAMINS ACD W/ FLUORIDE SOLN 0.25 MG/ML*** ACETAMINOPHEN SUSP 160 MG/5ML *LANCETS*** ALUMINUM HYDROXIDE-MAGNESIUM CARBONATE SUSP 508-475 MG/10ML SORAFENIB TOSYLATE TAB 200 MG (BASE EQUIVALENT) Y FLUTICASONE PROPIONATE NASAL SUSP 50 MCG/ACT *ADHESIVE BANDAGES*** *LANCETS*** *PEDIATRIC VITAMINS ACD W/ FLUORIDE SOLN 0.25 MG/ML*** FLUTICASONE PROPIONATE HFA INHAL AER 220 MCG/ACT (250/VALVE) CAPSAICIN CREAM 0.035% PROPAFENONE HCL CAP ER 12HR 425 MG DIPHENHYDRAMINE HCL LIQUID 12.5 MG/5ML POLYETHYLENE GLYCOL 3350 ORAL POWDER 17 GM/SCOOP CLOTRIMAZOLE CREAM 1% *LANCETS*** *MULTIPLE VITAMINS W/ MINERALS TAB** *MULTIPLE VITAMIN TAB** DIPHENHYDRAMINE HCL (SLEEP) CAP 50 MG CALCIUM TAB 500 MG CHLORHEXIDINE GLUCONATE DRESSING NIFEDIPINE TAB ER 24HR OSMOTIC RELEASE 60 MG HYOSCYAMINE SULFATE TAB ER 12HR 0.375 MG *VITAMINS W/ LIPOTROPICS TAB** NIFEDIPINE TAB ER 24HR OSMOTIC RELEASE 60 MG POLYETHYLENE GLYCOL-PROPYLENE GLYCOL PF OP SOLN 0.4-0.3% TRETINOIN CREAM 0.025% Y SIMETHICONE CHEW TAB 80 MG Appendix F9 3 Appendix F9. University of Maryland Health Partners (UMHP) Prescription Drugs Subject to NQTLs, by Delivery System Prior Authorization (PA) NQTL Fail First/Step Therapy (FF/ST) NQTL Prescription Drug Formulary Med/Surg Drugs Med/Surg Drugs DICLOFENAC SODIUM TAB DELAYED RELEASE 75 MG *ADHESIVE BANDAGES*** PIOGLITAZONE HCL TAB 45 MG (BASE EQUIV) ACETAMINOPHEN DISINTEGRATING TAB 80 MG ACETAMINOPHEN DISINTEGRATING TAB 160 MG INSULIN LISPRO PROT & LISPRO SUS PEN-INJ 100 UNIT/ML (50-50) *MULTIPLE VITAMINS W/ MINERALS TAB** ALUM & MAG HYDROXIDE-SIMETHICONE SUSP 200-200-20 MG/5ML CHOLECALCIFEROL DROPS 10 MCG/0.028ML (400 UNIT/0.028ML) INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32") DONEPEZIL HYDROCHLORIDE ORALLY DISINTEGRATING TAB 10 MG PYRIDOSTIGMINE BROMIDE TAB 60 MG DEXTROMETHORPHAN-GUAIFENESIN LIQUID 10-200 MG/5ML *LANCETS*** *MULTIPLE VITAMINS W/ MINERALS COMBINATION THERAPY PACK*** DIPHENHYDRAMINE HCL CAP 50 MG *MULTIPLE VITAMIN LIQUID** MISOPROSTOL TAB 100 MCG NORETHINDRONE-ETH ESTRADIOL TAB 0.5-35/1-35/0.5-35 MG-MCG NAPROXEN SODIUM TAB 220 MG PSEUDOEPHEDRINE W/ DM-GG LIQUID 30-10-100 MG/5ML GLIMEPIRIDE TAB 4 MG *PEDIATRIC MULTIPLE VITAMINS W/ IRON CHEW TAB 12 MG** *URINE GLUCOSE-KETONES TEST STRIPS*** GLYCERIN-HYPROMELLOSE-PEG 400 OPHTH SOLN 0.2-0.2-1% BECLOMETHASONE DIPROP HFA BREATH ACT INH AER 40 MCG/ACT *PEDIATRIC MULTIPLE VITAMIN W/ C & FA CHEW TAB** BISMUTH SUBSALICYLATE CHEW TAB 262 MG *ADHESIVE BANDAGES*** ATAZANAVIR SULFATE CAP 150 MG (BASE EQUIV) MISOPROSTOL TAB 200 MCG PSEUDOEPHEDRINE-GUAIFENESIN TAB ER 12HR 120-1200 MG CALCIUM & PHOSPHORUS W/ VITAMIN D TAB 105 MG-81 MG-120 UNIT Appendix F9 4 Appendix F9. University of Maryland Health Partners (UMHP) Prescription Drugs Subject to NQTLs, by Delivery System Prior Authorization (PA) NQTL Fail First/Step Therapy (FF/ST) NQTL Prescription Drug Formulary Med/Surg Drugs Med/Surg Drugs ASPIRIN CHEW TAB 81 MG CHOLECALCIFEROL CAP 25 MCG (1000 UNIT) CLINDAMYCIN HCL CAP 300 MG *LANCETS*** MICONAZOLE NITRATE VAGINAL CREAM 2% CARVEDILOL TAB 3.125 MG INTERFERON ALFA-2B INJ 10000000 UNIT/ML Y LEUPROLIDE ACETATE (4 MONTH) FOR SUBCUTANEOUS INJ KIT 30 MG Y CHLORHEXIDINE GLUCONATE SOLN 4% CLINDAMYCIN PALMITATE HCL FOR SOLN 75 MG/5ML (BASE EQUIV) CLOTRIMAZOLE CREAM 1% WATER FOR INJECT, BACTERIOSTATIC BENZYL ALCOHOL CALCIUM CITRATE-VITAMIN D TAB 315 MG-250 UNIT (ELEMENTAL CA) DEXTROMETHORPHAN-GUAIFENESIN SYRUP 10-100 MG/5ML ASPIRIN TAB DELAYED RELEASE 325 MG ELEXACAF-TEZACAF-IVACAF 100-50-75 MG &IVACAFTOR 150 MG TBPK Y CALCIUM CITRATE-VITAMIN D TAB 315 MG-250 UNIT (ELEMENTAL CA) CALCIUM TAB 600 MG FUROSEMIDE ORAL SOLN 8 MG/ML POLYETHYLENE GLYCOL 3350 ORAL PACKET 17 GM BISMUTH SUBSALICYLATE SUSP 262 MG/15ML NORETHINDRONE ACE & ETHINYL ESTRADIOL TAB 1.5 MG-30 MCG CELECOXIB CAP 400 MG Y CALCIUM CARBONATE-VITAMIN D TAB 600 MG-200 UNIT CALCIUM-MAGNESIUM-ZINC TAB 333-133-5 MG ALUM & MAG HYDROXIDE-SIMETHICONE SUSP 400-400-40 MG/5ML *LANCETS*** *SPACER/AEROSOL-HOLDING CHAMBERS - DEVICE*** *LANCETS*** *NEOMYCIN-BACITRACIN-POLYMYXIN OINT*** *LANCETS*** ERTUGLIFLOZIN-METFORMIN HCL TAB 7.5-1000 MG Y FOLIC ACID TAB 400 MCG Appendix F9 5 Appendix F9. University of Maryland Health Partners (UMHP) Prescription Drugs Subject to NQTLs, by Delivery System Prior Authorization (PA) NQTL Fail First/Step Therapy (FF/ST) NQTL Prescription Drug Formulary Med/Surg Drugs Med/Surg Drugs *LACTOBACILLUS TAB** POTASSIUM CITRATE TAB ER 5 MEQ (540 MG) CEFADROXIL CAP 500 MG PANCRELIPASE (LIP-PROT-AMYL) TAB 10440-39150-39150 UNIT CHOLECALCIFEROL CAP 125 MCG (5000 UNIT) SENNOSIDES TAB 8.6 MG SODIUM FLUORIDE CREAM 1.1% POTASSIUM BICARBONATE EFFER TAB 25 MEQ *MULTIPLE VITAMINS W/ MINERALS TAB** *MULTIPLE VITAMINS W/ MINERALS CAP** *MULTIPLE VITAMINS W/ MINERALS TAB** *MULTIPLE VITAMINS W/ MINERALS TAB** RILPIVIRINE HCL TAB 25 MG (BASE EQUIVALENT) *BIOFLAVONOID PRODUCTS TAB ER** LATANOPROST OPHTH SOLN 0.005% MONTELUKAST SODIUM ORAL GRANULES PACKET 4 MG (BASE EQUIV) LACTULOSE SOLUTION 10 GM/15ML *LANCETS*** NAPROXEN TAB EC 375 MG DOCUSATE SODIUM CAP 50 MG IBUPROFEN TAB 200 MG LORATADINE & PSEUDOEPHEDRINE TAB ER 24HR 10-240 MG ATENOLOL TAB 100 MG FEXOFENADINE-PSEUDOEPHEDRINE TAB ER 12HR 60-120 MG PRAZOSIN HCL CAP 2 MG CALCIUM CARBONATE-CHOLECALCIFEROL TAB 600 MG-800 UNIT *MULTIPLE VITAMIN TAB** *LANCETS*** *MULTIPLE URINE TEST STRIPS*** DARUNAVIR ETHANOLATE TAB 75 MG (BASE EQUIV) BETHANECHOL CHLORIDE TAB 50 MG PEG 3350-KCL-SOD BICARB-NACL FOR SOLN 420 GM PROPRANOLOL HCL ORAL SOLN 20 MG/5ML Appendix F9 6 Appendix F9. University of Maryland Health Partners (UMHP) Prescription Drugs Subject to NQTLs, by Delivery System Prior Authorization (PA) NQTL Fail First/Step Therapy (FF/ST) NQTL Prescription Drug Formulary Med/Surg Drugs Med/Surg Drugs *MULTIPLE VITAMINS W/ MINERALS TAB** CALCIUM CARBONATE (ANTACID) CHEW TAB 500 MG FOLIC ACID TAB 1 MG *SPECIALITY VITAMIN PRODUCT TAB** INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32") INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16") INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32") *MULTIPLE VITAMINS W/ MINERALS TAB** *LANCETS*** DEXTROMETHORPHAN-GUAIFENESIN SYRUP 10-100 MG/5ML CHLORPHENIRAMINE MALEATE TAB 4 MG *SPACER/AEROSOL-HOLDING CHAMBERS - DEVICE*** *PEDIATRIC MULTIPLE VITAMINS W/ FLUORIDE CHEW TAB 1 MG*** BENZOYL PEROXIDE GEL 10% ERGOCALCIFEROL TAB 50 MCG (2000 UNIT) *RESPIRATORY THERAPY SUPPLIES - MISC** INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16") NORETHINDRONE & ETHINYL ESTRADIOL TAB 1 MG-35 MCG SALINE NASAL SPRAY 0.65% LENVATINIB CAP THER PACK 2 X 10 MG & 4 MG (24 MG DAILY DOSE) Y INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16") *RESPIRATORY THERAPY SUPPLIES - MISC** *MULTIPLE VITAMIN CAP** *MULTIPLE VITAMINS W/ MINERALS TAB** LEVONORGESTREL TAB 1.5 MG *B-COMPLEX W/ MINERALS TAB** *ADHESIVE BANDAGES*** INSULIN LISPRO PROT & LISPRO SUS PEN-INJ 100 UNIT/ML (75-25) LEVOCARNITINE (DIETARY) ORAL SOLN 1 GM/10ML INSULIN LISPRO INJ 100 UNIT/ML *B-COMPLEX W/ C & FOLIC ACID TAB*** BETAMETHASONE DIPROPIONATE AUGMENTED OINT 0.05% *LACTOBACILLUS CAP** Appendix F9 7 Appendix F9.
Load more

Recommended publications
  • Nizatidine) Oral Solution
    Axid® (nizatidine) Oral Solution Description: Nizatidine (USP) is a histamine H2-receptor antagonist. Chemically, it is N-[2-[[[2-[(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1- ethenediamine. The structural formula is as follows: Nizatidine has the empirical formula C12H21N5O2S2 representing a molecular weight of 331.47. It is an off-white to buff crystalline solid that is soluble in water. Nizatidine has a bitter taste and mild sulfur-like odor. Axid® Oral Solution is formulated as a clear, yellow, oral solution with bubble gum flavor and each 1 mL contains 15 mg of nizatidine. Axid® Oral Solution also contains the inactive ingredients methylparaben, propylparaben, glycerin, sodium alginate, purified water, sodium chloride, saccharin sodium, sodium citrate dihydrate, citric acid anhydrous, sucrose, bubble gum flavor, artificial sweetness enhancer, and sodium hydroxide. Clinical Pharmacology in Adults: Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. Antisecretory Activity—1. Effects on Acid Secretion: Nizatidine significantly inhibited nocturnal gastric acid secretion for up to 12 hours. Nizatidine also significantly inhibited gastric acid secretion stimulated by food, caffeine, betazole, and pentagastrin (Table 1). Table 1. Effect of Oral Nizatidine on Gastric Acid Secretion % Inhibition of Gastric Acid Output by Dose (mg) Time After Dose (h) 20-50 75 100 150 300 Nocturnal Up to 10 57 - 73 - 90 Betazole Up to 3 - 93 - 100 99 Pentagon Up to 6 - 25 - 64 67 Meal Up to 4 41 64 - 98 97 Caffeine Up to 3 - 73 - 85 96 2. Effects on Other Gastrointestinal Secretions—Pepsin: Oral administration of 75 to 300 mg of nizatidine did not affect pepsin activity in gastric secretions.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Drug Consumption in 2017 - 2020
    Page 1 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A ALIMENTARY TRACT AND METABOLISM 322,79 3 312,53 4 303,08 4 298,95 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01AA Caries prophylactic agents 11,90 3 10,48 4 8,42 5 8,45 7 A01AA01 sodium fluoride 11,90 3 10,48 4 8,42 5 8,45 7 A01AA03 olaflur 0,00 - 0,00 - 0,00 - 0,00 - A01AB Antiinfectives for local oral treatment 2,36 8 2,31 7 2,31 7 2,02 7 A01AB03 chlorhexidine 2,02 6 2,10 7 2,09 7 1,78 7 A01AB11 various 0,33 21 0,21 0 0,22 0 0,24 0 A01AD Other agents for local oral treatment 0,02 0 0,03 0 0,04 0 - - A01AD02 benzydamine 0,02 0 0,03 0 0,04 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 71,13 3 69,32 3 68,35 3 A02A ANTACIDS 2,23 1 2,22 1 2,20 1 2,30 1 A02AA Magnesium compounds 0,07 22 0,07 22 0,08 22 0,10 19 A02AA04 magnesium hydroxide 0,07 22 0,07 22 0,08 22 0,10 19 A02AD Combinations and complexes of aluminium, 2,17 0 2,15 0 2,12 0 2,20 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 2,15 0 2,12 0 2,20 0 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 68,91 3 67,12 3 66,05 4 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 0,74 4 1,10 4 1,11 5 A02BA02 ranitidine 0,00 1 0,63 3 0,99 3 0,99 4 A02BA03 famotidine 0,16 7 0,11 8 0,11 10 0,12 9 A02BB Prostaglandins 0,04 62
    [Show full text]
  • Receptor Antagonist (H RA) Shortages | May 25, 2020 2 2 2 GERD4,5 • Take This Opportunity to Determine If Continued Treatment Is Necessary
    H2-receptor antagonist (H2RA) Shortages Background . 2 H2RA Alternatives . 2 Therapeutic Alternatives . 2 Adults . 2 GERD . 3 PUD . 3 Pediatrics . 3 GERD . 3 PUD . 4 Tables Table 1: Health Canada–Approved Indications of H2RAs . 2 Table 2: Oral Adult Doses of H2RAs and PPIs for GERD . 4 Table 3: Oral Adult Doses of H2RAs and PPIs for PUD . 5 Table 4: Oral Pediatric Doses of H2RAs and PPIs for GERD . 6 Table 5: Oral Pediatric Doses of H2RAs and PPIs for PUD . 7 References . 8 H2-receptor antagonist (H2RA) Shortages | May 25, 2020 1 H2-receptor antagonist (H2RA) Shortages BACKGROUND Health Canada recalls1 and manufacturer supply disruptions may be causing shortages of commonly used acid-reducing medications called histamine H2-receptor antagonists (H2RAs) . H2RAs include cimetidine, famotidine, nizatidine and ranitidine . 2 There are several Health Canada–approved indications of H2RAs (see Table 1); this document addresses the most common: gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) . 2 TABLE 1: HEALTH CANADA–APPROVED INDICATIONS OF H2RAs H -Receptor Antagonists (H RAs) Health Canada–Approved Indications 2 2 Cimetidine Famotidine Nizatidine Ranitidine Duodenal ulcer, treatment ü ü ü ü Duodenal ulcer, prophylaxis — ü ü ü Benign gastric ulcer, treatment ü ü ü ü Gastric ulcer, prophylaxis — — — ü GERD, treatment ü ü ü ü GERD, maintenance of remission — ü — — Gastric hypersecretion,* treatment ü ü — ü Self-medication of acid indigestion, treatment and prophylaxis — ü† — ü† Acid aspiration syndrome, prophylaxis — — — ü Hemorrhage from stress ulceration or recurrent bleeding, — — — ü prophylaxis ü = Health Canada–approved indication; GERD = gastroesophageal reflux disease *For example, Zollinger-Ellison syndrome .
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • 1: Gastro-Intestinal System
    1 1: GASTRO-INTESTINAL SYSTEM Antacids .......................................................... 1 Stimulant laxatives ...................................46 Compound alginate products .................. 3 Docuate sodium .......................................49 Simeticone ................................................... 4 Lactulose ....................................................50 Antimuscarinics .......................................... 5 Macrogols (polyethylene glycols) ..........51 Glycopyrronium .......................................13 Magnesium salts ........................................53 Hyoscine butylbromide ...........................16 Rectal products for constipation ..........55 Hyoscine hydrobromide .........................19 Products for haemorrhoids .................56 Propantheline ............................................21 Pancreatin ...................................................58 Orphenadrine ...........................................23 Prokinetics ..................................................24 Quick Clinical Guides: H2-receptor antagonists .......................27 Death rattle (noisy rattling breathing) 12 Proton pump inhibitors ........................30 Opioid-induced constipation .................42 Loperamide ................................................35 Bowel management in paraplegia Laxatives ......................................................38 and tetraplegia .....................................44 Ispaghula (Psyllium husk) ........................45 ANTACIDS Indications:
    [Show full text]
  • NTSAD Web Page on Miglustat Fran Platt Substrate Reduction Therapy
    NTSAD Web Page on Miglustat Fran Platt Substrate Reduction Therapy for LSDs Background Several lysosomal storage diseases (LSDs) involve the storage of fatty molecules within cells of the body that are called sphingolipids (1). This is because an enzyme that normally works to break these molecules down in the lysosome, the waste disposal/recycling center of our cells, does not work properly (2, 3). Some sphingolipids are modified by the cells of our bodies by adding sugars, creating a family of specialized sphingolipids called glycosphingolipids (GSLs) (1). For example, in Gaucher disease a glycosphingolipid called glucosylceramide is not broken down and is stored, whereas in Tay-Sachs and Sandhoff disease it is a glycosphingolipid called GM2 ganglioside that is stored (1). Glycosphingolipids are made in the cells of our bodies by a single metabolic pathway that begins with the addition of a sugar molecule called glucose to a sphingolipid molecule called ceramide (1). The fact that there is only a single major pathway to make most glycosphingolipids offers a potential way of treating these diseases using a small molecule drug (4). How would a drug work? The principle behind this treatment is called substrate reduction therapy (SRT)(4). The idea is to partially block the cells in our body from making glycosphingolipids, specifically stopping them from adding glucose to ceramide, which is the first step in this pathway. This would mean fewer glycosphingolipids are made, so fewer would require breaking down in the lysosome. The aim is to balance the rates of glycosphingolipid manufacture with their impaired rate of breakdown.
    [Show full text]
  • REVIEW Steroid Sulfatase Inhibitors for Estrogen
    99 REVIEW Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers Atul Purohit and Paul A Foster1 Oncology Drug Discovery Group, Section of Investigative Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, UK 1School of Clinical and Experimental Medicine, Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham B15 2TT, UK (Correspondence should be addressed to P A Foster; Email: [email protected]) Abstract Estrogens and androgens are instrumental in the maturation of in vivo and where we currently stand in regards to clinical trials many hormone-dependent cancers. Consequently,the enzymes for these drugs. STS inhibitors are likely to play an important involved in their synthesis are cancer therapy targets. One such future role in the treatment of hormone-dependent cancers. enzyme, steroid sulfatase (STS), hydrolyses estrone sulfate, Novel in vivo models have been developed that allow pre-clinical and dehydroepiandrosterone sulfate to estrone and dehydroe- testing of inhibitors and the identification of lead clinical piandrosterone respectively. These are the precursors to the candidates. Phase I/II clinical trials in postmenopausal women formation of biologically active estradiol and androstenediol. with breast cancer have been completed and other trials in This review focuses on three aspects of STS inhibitors: patients with hormone-dependent prostate and endometrial 1) chemical development, 2) biological activity, and 3) clinical cancer are currently active. Potent STS inhibitors should trials. The aim is to discuss the importance of estrogens and become therapeutically valuable in hormone-dependent androgens in many cancers, the developmental history of STS cancers and other non-oncological conditions.
    [Show full text]
  • Active Estrogen Synthesis and Its Function in Prostate Cancer-Derived Stromal Cells
    ANTICANCER RESEARCH 35: 221-228 (2015) Active Estrogen Synthesis and its Function in Prostate Cancer-derived Stromal Cells KAZUAKI MACHIOKA1, ATSUSHI MIZOKAMI1, YURI YAMAGUCHI2, KOUJI IZUMI1, SHINICHI HAYASHI3 and MIKIO NAMIKI1 1Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Ishikawa, Japan; 2Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan; 3Department of Molecular and Functional Dynamics, Graduate School of Medicine, Tohoku University, Sendai, Japan Abstract. Background: It remains unclear whether estrogen Castration-naïve prostate cancer (PCa) develops into is produced in prostate cancer (PCa) and how it functions in castration-resistant prostate cancer (CRPC) during androgen PCa. Materials and Methods: To examine the production of deprivation therapy (ADT) by various mechanisms. estrogen in PCa cells, the concentration of estrogen in the Especially, the androgen receptor (AR) signaling axis plays a medium in which LNCaP cells and PCa-derived stromal cells key role in this specific development. PCa cells mainly adapt (PCaSC) were co-cultured, was measured by liquid themselves to the environment of lower androgen chromatography-mass spectrometry/mass spectrometry (LC- concentrations and change into androgen-hypersensitive cells MS/MS), while aromatase (CYP19) mRNA expression was or androgen-independent cells. Androgens of adrenal origin confirmed by real-time polymerase chain reaction (RT-PCR) and their metabolites synthesized in the microenvironment in methods. To verify whether estrogen is synthesized from an intracrine/paracrine fashion act on surviving PCa cells and testosterone in PCaSC functions, PCaSC were co-cultured secrete prostate specific antigen (PSA). Therefore, new with breast cancer MCF-7-E10 cells, which were stably- recently developed medicines, abiraterone acetate that transfected with ERE-GFP, in the presence of testosterone.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1 Mutant Breast Tumours in Preclinical Models
    Author Manuscript Published OnlineFirst on March 28, 2016; DOI: 10.1158/0008-5472.CAN-15-2357 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Title: AZD9496: An oral estrogen receptor inhibitor that blocks the growth of ER- 2 positive and ESR1 mutant breast tumours in preclinical models. 3 4 Running title: Pharmacology of SERD inhibitor in breast cancer models 5 6 Hazel M. Weir,a Robert H. Bradbury,a Mandy Lawson,a Alfred A. Rabow,a David Buttar,a 7 Rowena J. Callis,b Jon O. Curwen,a Camila de Almeida,a Peter Ballard, a Michael Hulse,a 8 Craig S. Donald,a Lyman J. L. Feron,a Galith Karoutchi,a Philip MacFaul,a Thomas Moss,a 9 Richard A. Norman,b Stuart E. Pearson,a Michael Tonge,b Gareth Davies,a Graeme E. 10 Walker,b Zena Wilson,a Rachel Rowlinson,a Steve Powell,a Claire Sadler,a Graham 11 Richmond,a Brendon Ladd, d Ermira Pazolli,c Anne Marie Mazzola,d Celina D’Cruz,d Chris 12 De Savi.d 13 14 Authors’ Affiliations: 15 aOncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, UK; 16 bDiscovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG UK; c 17 H3 Biomedicine, Technology Sq, Cambridge, MA 02139,dOncology iMed, AstraZeneca R&D 18 Boston, Gatehouse Drive, Waltham, MA 02451, U.S. 19 20 Key words: SERD, estrogen receptor, metastatic breast cancer, ER mutation, ESR1 mutation. 21 combination therapy 22 23 Corresponding author: [email protected] 24 25 Disclosure of Potential Conflicts of Interest: All authors are present or past employees of 26 AstraZeneca Pharmaceuticals 27 28 Tables: 1 29 Figures: 6 30 Supplementary Tables:4 31 Supplementary Figures: 7 32 33 Precis: This article discloses the structure and pharmacology of an oral non-steroidal small 34 molecule which is potent against wild-type and mutant forms of the estrogen receptor, 35 producing anti-tumour efficacy either as a monotherapy or in combination with PI3K or cell 36 cycle inhibitors in vivo.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]